Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

US FDA approves Novo Nordisk’s Wegovy to treat metabolic dysfunction-associated steatohepatitis: Bagsværd, Denmark Monday, August 18, 2025, 11:00 Hrs [IST] Novo Nordisk, a lead ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...